← All diseases Infectious diseases

Chronic hepatitis C

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest quality evidence only (79)Meta-analysis (20)Treatment guideline (4)Phase 3 study (27)Randomized trial (14)Systematic review (14)Clinical trial (677)Review article (146)Early study (phase 1 or 2) (11)Case report (85)Laboratory or animal study (8)Commentary or editorial (53)Retracted publication (2) Studies currently recruiting participants only (15)

Filter

Publications (1342)

• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Strategy for early detection of viral hepatitis in patients with a request for liver biochemistry profile and hypertransaminasemia. (2025/01/01) ♡
• Heterogeneous development of liver fibrosis in chronic hepatitis C patients; assessment by extracellular volume fraction map generated from routine clinical CT data. (2025/01/01) ♡
• UPLC Estimate of Sofosbuvir and Ledipasvir Utilizing Greenness Tool in Conjunction With an Analytical Quality by Design. (2025/01/01) ♡
• HLA-G liver expression in chronically HIV/hepatitis C-coinfected individuals. (2025/01/01) ♡
• Residual HCV-RNA and Elevated Platelet-to-Lymphocyte Ratio Predict Poor Long-Term Outcomes in Patients with Chronic Hepatitis C After Treatment. (2025/01/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. MASLD after hepatitis C virus eradication: Do not overlook the cardiometabolic risk factors: Editorial on "Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan". (2025/01/01) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. (2025/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Hepatitis C virus microelimination program in hemodialysis patients: success of a multi-stakeholder partnership based on a national eradication strategy. (2025/01/01) ♡
• Evaluation of liver fibrosis in HCV-infected patients using two-dimensional shear-wave elastography (2D-SWE) before and after antiviral treatment. (2024/12/31) ♡
• [Analysis of HCV genotype distribution characteristics in the Hotan region]. (2024/12/30) ♡
• [Analysis of the efficacy and safety profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of patients with chronic hepatitis C with failed DAAs therapy]. (2024/12/30) ♡
• Direct-Acting Antivirals in Hepatitis C Treatment for Renal Impairment: Liver Safety Concerns and Effectiveness in Peritoneal Dialysis. (2024/12/29) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hepatitis C Virus-Pediatric and Adult Perspectives in the Current Decade. (2024/12/29) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Comorbidities, drug-resistance and length of hospital stay among tuberculosis inpatients in Northeastern China: a retrospective observational study from 2013 to 2021. (2024/12/28) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Effectiveness of 8-week Treatment with Glecaprevir/Pibrentasvir in Treatment-naïve or -experienced HCV Patients: Results from an Observational Retrospective Study in Real-life Settings (ODYSSEY). (2024/12/28) ♡
• Impact of Age and Sex on Viral Load in Hepatitis C Virus Infection. (2024/12/27) ♡
• Elevated serum neprilysin levels in patients with chronic hepatitis C and metabolic dysfunction-associated steatotic liver disease: hepatic oxidative stress as an underlying mechanism. (2024/12/26) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Hepatitis C virus-related hepatitis flare after immunochemotherapy in a patient with follicular lymphoma. (2024/12/25) ♡
• PLASMA EXPRESSION LEVELS OF MICRORNA-21 MIGHT HELP IN THE DETECTION OF HCV PATIENTS COMPLICATED BY HEPATOCELLULAR CARCINOMA. (2024/12/20) ♡
• EARLY NONINVASIVE EVALUATION OF LIVER FIBROSIS AFTER HEPATITIS C TREATMENT: THE IMPACT OF INFLAMMATION. (2024/12/20) ♡
• Five-Year Sustained Response to Nivolumab in Hepatocellular Carcinoma following Serious Immune-Related Hepatitis. (2024/12/20) ♡
• Modeling of randomized hepatitis C vaccine trials: Bridging the gap between controlled human infection models and real-world testing. (2024/12/18) ♡
• Immune checkpoint proteins are associated with persistently high liver stiffness after successful HCV treatment in people with HIV: a retrospective study. (2024/12/17) ♡
• Retracted publicationiThis research has been withdrawn by science itself, for example due to a flaw in the method or unreliable data. Do not use it as support and do not discuss it as evidence. Outcomes of Direct-Acting Antivirals Versus Interferon-Based Therapy in Chronic Hepatitis C Infection. (2024/12/17) ♡
• Treatment of Hepatitis C Virus Infections Among Patients of Ukrainian Origin During the Influx of War Refugees to Poland. (2024/12/15) ♡
• HCV Treatment Outcomes in PWID: Impact of Addiction History on SVR12. (2024/12/11) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter? (2024/12/10) ♡
• Human genetic variation reveals FCRL3 is a lymphocyte receptor for Yersinia pestis. (2024/12/08) ♡
• Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients. (2024/12/03) ♡
• Real-world experience in treatment of donor-derived Hepatitis C virus in kidney transplant recipients with delayed initiation, shortened course glecaprevir/pibrentasvir versus standard of care. (2024/12/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study. (2024/12/01) ♡
• Diversity, geographical distribution and predictive factors of Hepatitis C virus genotypes and subtypes in Rwanda. (2024/12/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis. (2024/12/01) ♡
• Uptake of guideline-based testing for chronic viral hepatitis in Australian primary care: retrospective analysis of electronic medical record data. (2024/12/01) ♡
• Potential Role of the Tie2/ Angiopoietin System in Hepatitis C Virus- Induced Hepatocellular Carcinoma. (2024/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Clinical Advantages of Phlebotomy: An Umbrella Review of Meta-Analyses. (2024/12/01) ♡
• Prevalence and risk factors of liver fibrosis in patients with metabolic-associated fatty liver disease undergoing bariatric surgery. (2024/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hepatitis C Virus-Core Antigen: Implications in Diagnostic, Treatment Monitoring and Clinical Outcomes. (2024/11/29) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Multifaceted Role of Bilirubin in Liver Disease: A Literature Review. (2024/11/28) ♡
• Comparison of different noninvasive scores for assessing hepatic fibrosis in a cohort of chronic hepatitis C patients. (2024/11/28) ♡
• Association between the systemic immune-inflammation index and the outcome of liver fibrosis in patients with chronic hepatitis C. (2024/11/26) ♡
• Effectiveness of sofosbuvir-based treatments for patients with hepatitis C virus genotype 6 infection: a real-world study from East China. (2024/11/26) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Chronic Hepatitis C: A Real-life Study in Northeastern Brazil. (2024/11/25) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Metabolic Dysfunction-Associated Steatotic Liver Disease in Chronic Hepatitis C Virus Infection: From Basics to Clinical and Nutritional Management. (2024/11/24) ♡
• Different dynamics of soluble inflammatory mediators after clearance of respiratory SARS-CoV-2 versus blood-borne hepatitis C virus infections. (2024/11/22) ♡
• Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals. (2024/11/15) ♡
• Liver Dysfunction in Hyperthyroidism. (2024/11/08) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Cholangiolocellular Carcinoma Misdiagnosed As Hemangioma: Unique Central Fibrotic Area Devoid of Cancer Cells Detected on a Seven-Year Follow-Up. (2024/11/05) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Efficacy of 8-week daclatasvir-sofosbuvir regimen in chronic hepatitis C: a systematic review and meta-analysis. (2024/11/04) ♡
• Changing global epidemiology of chronic hepatitis C virus-related outcomes from 2010 to 2019: cirrhosis is the growing burden of hepatitis C virus-related disease. (2024/11/01) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.